Last reviewed · How we verify
NCT02478827
A Trial of Cognitive Training in Schizophrenia
NA trial testing Cognitive training in Schizophrenia in 83 participants. Completed in 31 August 2017.
31 August 2017
Quick facts
| Lead sponsor | University of Calgary |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 83 |
| Start date | 1 March 2016 |
| Primary completion | 31 August 2017 |
| Estimated completion | 31 August 2017 |
| Sites | 3 locations across Canada |
Drugs / interventions tested
- Cognitive training
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
University of Calgary
Who can join
Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Schizophrenia is associated with a wide range of symptoms impacting a number of different domains, including cognitive impairment. Given the array of cognitive deficits associated with schizophrenia and their relationship to daily functioning, numerous research groups have examined the impact of cognitive remediation on many aspects of cognition. However, it is currently unclear as to which domains of cognition should be targeted to produce the most widespread and durable benefits for schizophrenia patients. It may be the case that targeting lower-level cognitive processes that are important for higher-level and more complex aspects of cognition may produce the most widespread benefits in cognition and everyday functioning. Relatively few studies have examined the effects of working memory or processing speed training on individuals with schizophrenia, as most studies examine broad-based remediation programs. Thus, there is a need for targeted working memory and processing speed training studies to better understand the mechanisms of cognitive enhancement through training in patients. This study will aim to: 1) investigate near-transfer gains associated with working memory and processing speed training in schizophrenia patients, 2) investigate far-transfer gains associated with working memory and processing speed training (i.e., gains in other neurocognitive domains and social cognition), and 3) investigate real-world gains associated with training (i.e., gains in daily functioning). Towards this aim, 81 schizophrenia patients will be recruited and randomly assigned to a working memory training group, a processing speed training group, or a no training control group. Training will be completed at home for 30 minutes per day, 5 days per week, for a total of 10 weeks. Neurocognitive, social cognitive, and daily functioning measures will be administered both pre- and post-training to detect training-related gains.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Working memory and processing speed training in schizophrenia: study protocol for a randomized controlled trial.
Cassetta BD, Goghari VM. · · 2016 · cited 13× · PMID 26812902 · DOI 10.1186/s13063-016-1188-5
Verify or expand the search:
- PubMed search for NCT02478827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cognitive training
Trials testing the same drug.
- NCT07414537 — Remotely Administered tDCS to Improve Cognitive Function in Veterans With mTBI and PTSD Principal Investigator · Phase 2 · not yet recruiting
- NCT07447037 — Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure · NA · not yet recruiting
- NCT04664790 — Hyperbaric Oxygen Therapy Compared to Cognitive Training in FASD · NA · not yet recruiting
- NCT07283276 — Effect of Functional Core Stability Training or Cognitive Training on Balance and Postural Control in Chronic Ankle Inst · NA · recruiting
- NCT06338774 — Cognitive Control to Boost Physical Activity Adherence · NA · recruiting
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other University of Calgary trials
Trials by the same sponsor.
- NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
- NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
- NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
- NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
- NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02478827 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Calgary
- Last refreshed: 10 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02478827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing